Cargando…
Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374298/ https://www.ncbi.nlm.nih.gov/pubmed/25887385 http://dx.doi.org/10.1186/s12879-015-0855-6 |
_version_ | 1782363467194302464 |
---|---|
author | Bow, Eric J Vanness, David J Slavin, Monica Cordonnier, Catherine Cornely, Oliver A Marks, David I Pagliuca, Antonio Solano, Carlos Cragin, Lael Shaul, Alissa J Sorensen, Sonja Chambers, Richard Kantecki, Michal Weinstein, David Schlamm, Haran |
author_facet | Bow, Eric J Vanness, David J Slavin, Monica Cordonnier, Catherine Cornely, Oliver A Marks, David I Pagliuca, Antonio Solano, Carlos Cragin, Lael Shaul, Alissa J Sorensen, Sonja Chambers, Richard Kantecki, Michal Weinstein, David Schlamm, Haran |
author_sort | Bow, Eric J |
collection | PubMed |
description | BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. METHODS: Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive candidiasis, all-cause mortality, and use of other antifungals) were extracted from eligible RCTs and incorporated into a Bayesian hierarchical random-effects MTC. RESULTS: Five eligible RCTs, randomizing 2147 patients in total, were included. Relative to fluconazole, prophylaxis with itraconazole (odds ratio [OR]: 0.52; interquartile range [IQR]: 0.35–0.76), posaconazole (OR: 0.56; IQR: 0.32–0.99), and voriconazole (OR: 0.46; IQR: 0.28–0.73) reduced incidence of overall proven/probable IFI. Posaconazole (OR: 0.31; IQR: 0.17–0.58) and voriconazole (OR: 0.33; IQR: 0.17–0.58) prophylaxis reduced proven/probable invasive aspergillosis more than itraconazole (OR: 0.68; IQR: 0.42–1.12). All-cause mortality was similar across all mould-active agents. CONCLUSION: As expected, mould-active azoles prevented IFIs, particularly invasive aspergillosis, more effectively than fluconazole in alloHCT recipients. The paucity of comparative efficacy data suggests that other factors such as long-term tolerability, availability of intravenous formulations, local IFI epidemiology, and drug costs may need to form the basis for selection among the mould-active azoles. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0855-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4374298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43742982015-03-27 Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients Bow, Eric J Vanness, David J Slavin, Monica Cordonnier, Catherine Cornely, Oliver A Marks, David I Pagliuca, Antonio Solano, Carlos Cragin, Lael Shaul, Alissa J Sorensen, Sonja Chambers, Richard Kantecki, Michal Weinstein, David Schlamm, Haran BMC Infect Dis Research Article BACKGROUND: Antifungal prophylaxis is a promising strategy for reducing invasive fungal infections (IFIs) in allogeneic hematopoietic cell transplant (alloHCT) recipients, but the optimum prophylactic agent is unknown. We used mixed treatment comparison (MTC) meta-analysis to compare clinical trials examining the use of oral antifungals for prophylaxis in alloHCT recipients, with the goal of informing medical decision-making. METHODS: Randomized controlled trials (RCTs) of fluconazole, itraconazole, posaconazole, and voriconazole for primary antifungal prophylaxis were identified through a systematic literature review. Outcomes of interest (incidence of IFI/invasive aspergillosis/invasive candidiasis, all-cause mortality, and use of other antifungals) were extracted from eligible RCTs and incorporated into a Bayesian hierarchical random-effects MTC. RESULTS: Five eligible RCTs, randomizing 2147 patients in total, were included. Relative to fluconazole, prophylaxis with itraconazole (odds ratio [OR]: 0.52; interquartile range [IQR]: 0.35–0.76), posaconazole (OR: 0.56; IQR: 0.32–0.99), and voriconazole (OR: 0.46; IQR: 0.28–0.73) reduced incidence of overall proven/probable IFI. Posaconazole (OR: 0.31; IQR: 0.17–0.58) and voriconazole (OR: 0.33; IQR: 0.17–0.58) prophylaxis reduced proven/probable invasive aspergillosis more than itraconazole (OR: 0.68; IQR: 0.42–1.12). All-cause mortality was similar across all mould-active agents. CONCLUSION: As expected, mould-active azoles prevented IFIs, particularly invasive aspergillosis, more effectively than fluconazole in alloHCT recipients. The paucity of comparative efficacy data suggests that other factors such as long-term tolerability, availability of intravenous formulations, local IFI epidemiology, and drug costs may need to form the basis for selection among the mould-active azoles. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0855-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-17 /pmc/articles/PMC4374298/ /pubmed/25887385 http://dx.doi.org/10.1186/s12879-015-0855-6 Text en © Bow et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bow, Eric J Vanness, David J Slavin, Monica Cordonnier, Catherine Cornely, Oliver A Marks, David I Pagliuca, Antonio Solano, Carlos Cragin, Lael Shaul, Alissa J Sorensen, Sonja Chambers, Richard Kantecki, Michal Weinstein, David Schlamm, Haran Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title_full | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title_fullStr | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title_full_unstemmed | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title_short | Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
title_sort | systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374298/ https://www.ncbi.nlm.nih.gov/pubmed/25887385 http://dx.doi.org/10.1186/s12879-015-0855-6 |
work_keys_str_mv | AT bowericj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT vannessdavidj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT slavinmonica systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT cordonniercatherine systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT cornelyolivera systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT marksdavidi systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT pagliucaantonio systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT solanocarlos systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT craginlael systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT shaulalissaj systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT sorensensonja systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT chambersrichard systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT kanteckimichal systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT weinsteindavid systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients AT schlammharan systematicreviewandmixedtreatmentcomparisonmetaanalysisofrandomizedclinicaltrialsofprimaryoralantifungalprophylaxisinallogeneichematopoieticcelltransplantrecipients |